The latter finding points to a novel mechanism to counteract pulmonary hypertension and implicates a potential therapeutic usage of KCa2.3/KCa3.1 activators for the treatment of pulmonary hypertension. The gene discussed is KCNN4; the disease is pulmonary arterial hypertension.